Close Menu

NEW YORK (GenomeWeb) – Becton Dickinson reported today that its fiscal second quarter revenues decreased approximately 1 percent year over year.

On a comparable, currency-neutral basis, Q2 revenues increased more than 3 percent, BD said.

For the three months ended March 31, BD posted revenues of $4.20 billion compared to $4.22 billion in the year-ago quarter and below the analysts' average estimate of $4.24 billion.

BD's Medical segment revenues were up less than 1 percent to $2.18 billion from $2.17 billion a year ago. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.